PrecisionDX Lab specializes in quantitative confirmation urine drug testing using research-grade LC-MS/MS technology to optimize cutoff levels, thereby reducing false negatives and enhancing patient care. Their VerifID solution employs DNA matching to ensure accurate specimen identification, addressing the critical issue of sample misidentification in drug testing.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional urine drug testing methods often produce false negatives due to suboptimal cutoff levels, and sample misidentification can compromise the accuracy and reliability of results, undermining patient care and treatment decisions. Managing the drug testing process, including scheduling, randomization, and adherence monitoring, can be cumbersome and inefficient for healthcare providers. Furthermore, the risk of adverse drug interactions necessitates careful review of patient medication regimens, which can be time-consuming and prone to errors without adequate decision support.
Solution
PrecisionDX Lab offers a suite of solutions designed to enhance the accuracy, efficiency, and safety of drug testing and medication management. The NextGen service utilizes research-grade LC-MS/MS technology to optimize cutoff levels in urine drug tests, reducing false negatives and providing reliable data for timely interventions. VerifID employs DNA matching to ensure accurate specimen identification, preventing sample misidentification and safeguarding against fraudulent activities. UpNext streamlines drug testing management with automated scheduling, protocol customization, and efficient randomization methods, reducing administrative burden and improving patient adherence. The DDI platform leverages Elsevier's Gold Standard Drug Database to identify potential drug-to-drug interactions, providing healthcare providers with critical decision support to prevent adverse events and optimize therapeutic outcomes.
Target Audience
The primary target audience includes healthcare providers, hospitals, and clinical laboratories seeking to improve the accuracy, efficiency, and safety of drug testing and medication management.
Features
- **NextGen:** Quantitative urine drug testing using LC-MS/MS technology with optimized cutoff levels to minimize false negatives.
- **VerifID:** DNA matching technology to verify patient identity and ensure accurate specimen authentication.
- **UpNext:** Automated scheduling and protocol customization for drug testing management, ensuring compliance with payer policies.
- **UpNext:** Structured, automated randomization processes for increased transparency and consistency in testing.
- **UpNext:** Rapid 24-48 hour turnaround time for test results, enabling timely clinical decisions.
- **DDI:** Integration of Elsevier's Gold Standard Drug Database for identifying potential drug-to-drug interactions.
- **DDI:** Seamless integration of DDI intelligence into test reports for easy access within the clinical workflow.